Last 47 quarters of trend data · Healthcare · Medical - Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 24.87 | 20.90 | 18.53 | 32.11 | 21.23 | 29.61 | 31.09 | 22.01 | 21.94 | 22.99 | 39.28 | 15.14 | 36.44 | 36.40 | 29.10 | — | 28.41 | 35.98 | 473.00 | — | 51.45 |
| — | -29.4% | -40.4% | +45.9% | -3.2% | +28.8% | -20.8% | +45.4% | -39.8% | -36.8% | +35.0% | — | +28.2% | +1.2% | -93.8% | — | -44.8% | -38.2% | +1045.2% | — | +80.7% | |
| P/S Ratio | 2.08 | 1.91 | 2.12 | 1.98 | 2.45 | 2.18 | 2.96 | 2.61 | 3.00 | 2.88 | 3.60 | 3.27 | 3.36 | 4.09 | 3.71 | 3.66 | 3.29 | 3.10 | 4.04 | 3.16 | 4.44 |
| — | -12.4% | -28.3% | -23.9% | -18.6% | -24.5% | -17.8% | -20.2% | -10.6% | -29.4% | -3.0% | -10.7% | +2.1% | +31.8% | -8.1% | +16.0% | -25.8% | -33.5% | -20.7% | -15.8% | +24.3% | |
| P/B Ratio | 1.38 | 1.31 | 1.40 | 1.40 | 1.53 | 1.44 | 1.82 | 1.69 | 1.77 | 1.76 | 2.16 | 2.03 | 1.88 | 2.47 | 2.24 | 2.22 | 1.79 | 1.82 | 2.24 | 2.03 | 2.35 |
| — | -8.9% | -23.3% | -17.2% | -13.3% | -17.9% | -15.6% | -16.8% | -6.0% | -28.8% | -3.4% | -8.5% | +4.9% | +35.5% | +0.0% | +9.4% | -23.7% | -30.2% | -14.7% | -20.8% | +1.5% | |
| P/FCF | 11.60 | 5.79 | 13.71 | 6.66 | 8.97 | 15.17 | 16.83 | 12.53 | 14.86 | 25.11 | 52.50 | 12.08 | 26.63 | 38.53 | 27.51 | 36.99 | 13.62 | 17.73 | 33.46 | 21.88 | 19.21 |
| — | -61.8% | -18.5% | -46.8% | -39.7% | -39.6% | -67.9% | +3.7% | -44.2% | -34.8% | +90.8% | -67.4% | +95.6% | +117.4% | -17.8% | +69.1% | -29.1% | -7.4% | -9.5% | +11.0% | -2.1% | |
| EV / EBITDA | 9.78 | 18.04 | 11.56 | 10.82 | 10.40 | 10.98 | 12.98 | 10.26 | 13.10 | 11.70 | 16.16 | 12.91 | 14.16 | 15.85 | 14.60 | 40.05 | 14.24 | 13.50 | 18.94 | 23.42 | 19.16 |
| — | +64.4% | -11.0% | +5.4% | -20.6% | -6.2% | -19.7% | -20.5% | -7.5% | -26.2% | +10.7% | -67.8% | -0.6% | +17.4% | -22.9% | +71.0% | -25.7% | -37.3% | -5.8% | +22.8% | +22.7% | |
| EV / EBIT | 17.62 | 18.04 | 16.45 | 36.40 | 18.61 | 20.65 | 24.05 | 19.09 | 24.42 | 19.68 | 30.68 | 22.95 | 26.60 | 27.37 | 24.36 | — | 30.87 | 29.09 | 57.51 | — | 37.49 |
| — | -12.6% | -31.6% | +90.7% | -23.8% | +4.9% | -21.6% | -16.8% | -8.2% | -28.1% | +25.9% | — | -13.9% | -5.9% | -57.6% | — | -17.7% | -31.7% | +54.1% | — | +33.3% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.6% | 70.8% | 72.4% | 64.7% | 72.1% | 71.5% | 71.2% | 71.0% | 70.5% | 71.5% | 72.9% | 72.2% | 70.4% | 71.9% | 72.6% | 71.5% | 70.8% | 71.3% | 69.9% | 67.5% | 70.8% |
| — | -1.0% | +1.7% | -8.9% | +2.2% | -0.0% | -2.3% | -1.7% | +0.1% | -0.6% | +0.3% | +1.0% | -0.5% | +0.8% | +3.9% | +5.9% | -0.1% | -0.7% | -3.9% | -2.1% | +0.5% | |
| Operating Margin | 16.5% | 15.0% | 17.9% | 12.8% | 17.6% | 14.4% | 15.3% | 19.2% | 15.3% | 18.1% | 14.1% | 18.3% | 15.2% | 17.6% | 17.9% | -1.6% | 14.7% | 15.8% | 11.9% | 3.9% | 14.4% |
| — | +3.7% | +16.8% | -33.3% | +14.6% | -20.2% | +8.8% | +5.3% | +0.8% | +2.6% | -21.3% | +1277.4% | +3.5% | +11.8% | +49.9% | -139.9% | +1.9% | +23.7% | -26.2% | -66.4% | -7.0% | |
| Net Margin | 8.6% | 9.1% | 11.4% | 6.2% | 11.5% | 7.4% | 9.5% | 11.8% | 13.7% | 12.5% | 9.1% | 21.6% | 9.3% | 11.2% | 12.7% | -7.2% | 11.6% | 8.6% | 0.9% | -4.1% | 8.6% |
| — | +23.8% | +19.7% | -47.5% | -15.5% | -41.2% | +4.5% | -45.2% | +47.2% | +11.5% | -28.1% | +402.2% | -20.1% | +30.0% | +1387.2% | -73.5% | +34.5% | +7.2% | -93.1% | -125.8% | -31.3% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 5.6% | 1.6% | 1.9% | 1.1% | 1.8% | 1.2% | 1.5% | 1.9% | 2.0% | 1.9% | 1.4% | 3.4% | 1.3% | 1.7% | 1.9% | -1.1% | 1.6% | 1.3% | 0.1% | -0.7% | 1.2% |
| — | +27.9% | +28.3% | -43.2% | -7.9% | -36.1% | +6.4% | -42.5% | +51.7% | +12.2% | -28.5% | +412.0% | -17.9% | +34.2% | +1571.9% | -62.4% | +38.3% | +12.3% | -92.8% | -123.9% | -44.2% | |
| ROA | 3.2% | 0.9% | 1.0% | 0.6% | 1.0% | 0.7% | 0.8% | 1.1% | 1.2% | 1.1% | 0.8% | 2.0% | 0.8% | 1.0% | 1.1% | -0.6% | 0.9% | 0.7% | 0.1% | -0.4% | 0.6% |
| — | +28.4% | +24.4% | -46.1% | -13.5% | -40.0% | +4.1% | -43.4% | +50.5% | +14.7% | -27.0% | +418.8% | -15.6% | +38.1% | +1644.4% | -73.9% | +50.2% | +21.3% | -92.3% | -125.7% | -40.6% | |
| ROIC | 5.4% | 1.2% | 1.4% | 1.1% | 1.3% | 1.2% | 1.2% | 1.6% | 1.2% | 1.5% | 1.1% | 1.5% | 1.1% | 1.4% | 1.4% | -0.1% | 1.0% | 1.2% | 0.8% | 0.3% | 0.9% |
| — | +4.1% | +17.9% | -31.3% | +17.0% | -18.2% | +8.4% | +7.2% | +2.1% | +4.3% | -20.7% | +1324.3% | +7.8% | +18.2% | +75.7% | -139.8% | +11.0% | +36.6% | -19.5% | -67.1% | -19.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.59 | 0.59 | 0.59 | 0.59 | 0.64 | 0.60 | 0.58 | 0.50 | 0.52 | 0.46 | 0.46 | 0.46 | 0.44 | 0.46 | 0.48 | 0.47 | 0.47 | 0.50 | 0.52 | 0.56 | 0.59 |
| — | -2.0% | +1.9% | +19.0% | +22.0% | +31.9% | +25.7% | +7.6% | +18.9% | -0.7% | -3.4% | -2.4% | -6.1% | -7.2% | -9.1% | -15.1% | -21.0% | -20.4% | -16.8% | -16.2% | -15.4% | |
| Debt / EBITDA | 3.06 | 22.80 | 13.96 | 13.15 | 12.78 | 13.24 | 13.13 | 9.51 | 12.16 | 9.81 | 11.49 | 9.69 | 10.80 | 10.07 | 10.36 | 28.45 | 11.99 | 11.73 | 14.58 | 20.42 | 15.76 |
| — | +72.2% | +6.3% | +38.3% | +5.1% | +34.9% | +14.3% | -1.9% | +12.6% | -2.5% | +10.9% | -66.0% | -9.9% | -14.2% | -29.0% | +39.4% | -24.0% | -31.2% | -8.1% | +27.2% | +6.1% | |
| Current Ratio | 1.98 | 1.69 | 1.73 | 1.98 | 2.43 | 1.87 | 2.44 | 1.91 | 1.36 | 1.29 | 1.66 | 1.61 | 2.11 | 1.96 | 1.89 | 1.88 | 1.98 | 1.81 | 1.69 | 1.41 | 1.81 |
| — | -9.7% | -28.9% | +4.0% | +78.3% | +45.6% | +47.1% | +18.2% | -35.5% | -34.5% | -12.3% | -14.1% | +6.9% | +8.4% | +11.8% | +33.3% | +9.3% | -1.0% | -29.4% | -29.1% | -20.5% | |
| Quick Ratio | 1.10 | 1.69 | 0.95 | 1.10 | 1.39 | 0.96 | 1.46 | 0.99 | 0.70 | 0.63 | 0.80 | 0.78 | 0.99 | 0.95 | 0.93 | 0.97 | 1.05 | 0.95 | 0.89 | 0.79 | 0.95 |
| — | +75.6% | -35.0% | +10.3% | +99.6% | +53.1% | +81.8% | +27.7% | -29.4% | -33.5% | -13.7% | -19.5% | -5.6% | -0.5% | +4.2% | +22.5% | +10.2% | -1.5% | -25.1% | -23.3% | -19.0% | |
| Interest Coverage | 3.84 | 4.50 | 5.47 | 2.36 | 4.70 | 3.83 | 4.46 | 5.67 | 5.24 | 6.91 | 5.24 | 6.66 | 5.29 | 6.36 | 6.95 | -0.76 | 5.20 | 6.14 | 3.46 | -1.84 | 4.63 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ZBH stock.
Zimmer Biomet Holdings, Inc.'s current P/E is 24.9x. The average P/E over the last 4 quarters is 23.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Zimmer Biomet Holdings, Inc.'s current operating margin is 16.5%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Zimmer Biomet Holdings, Inc.'s business trajectory between earnings reports.